These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33869725)

  • 21. Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer's Disease Continuum.
    Chen YH; Lin RR; Huang HF; Xue YY; Tao QQ
    Front Aging Neurosci; 2022; 14():848180. PubMed ID: 35847667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.
    Mo Y; Stromswold J; Wilson K; Holder D; Sur C; Laterza O; Savage MJ; Struyk A; Scheltens P; Teunissen CE; Burke J; Macaulay SL; Bråthen G; Sando SB; White LR; Weiss C; Cowes A; Bush MM; DeSilva G; Darby DG; Rainey-Smith SR; Surls J; Sagini E; Tanen M; Altman A; Luthman J; Egan MF
    Alzheimers Dement (Amst); 2017; 6():201-209. PubMed ID: 28349119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.
    Edsbagge M; Andreasson U; Ambarki K; Wikkelsø C; Eklund A; Blennow K; Zetterberg H; Tullberg M
    J Alzheimers Dis; 2017; 58(3):821-828. PubMed ID: 28505972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Periodontal Pathogens and Associated Intrathecal Antibodies in Early Stages of Alzheimer's Disease.
    Laugisch O; Johnen A; Maldonado A; Ehmke B; Bürgin W; Olsen I; Potempa J; Sculean A; Duning T; Eick S
    J Alzheimers Dis; 2018; 66(1):105-114. PubMed ID: 30223397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal Fluid Levels of Amyloid Beta 1-43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study.
    Lauridsen C; Sando SB; Shabnam A; Møller I; Berge G; Grøntvedt GR; Bakken IJ; Salvesen Ø; Bråthen G; White LR
    Front Aging Neurosci; 2016; 8():30. PubMed ID: 26973507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
    Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ
    Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrospinal Fluid Levels of β-Amyloid 40 and β-Amyloid 42 are Proportionately Decreased in Amyloid Positron-Emission Tomography Negative Idiopathic Normal-Pressure Hydrocephalus Patients.
    Kim HJ; Lim TS; Lee SM; Kim TS; Kim Y; An YS; Youn YC; Park SA; Chang J; Moon SY
    J Clin Neurol; 2019 Jul; 15(3):353-359. PubMed ID: 31286708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
    Guo T; Landau SM; Jagust WJ;
    Alzheimers Res Ther; 2021 Oct; 13(1):174. PubMed ID: 34654465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamic changes of CSF clusterin levels across the Alzheimer's disease continuum.
    Tang L; Wang ZB; Ma LZ; Cao XP; Tan L; Tan MS
    BMC Neurol; 2022 Dec; 22(1):508. PubMed ID: 36581903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer's Disease, But Has Similar Diagnostic Accuracy to Aβ42.
    Lauridsen C; Sando SB; Møller I; Berge G; Pomary PK; Grøntvedt GR; Salvesen Ø; Bråthen G; White LR
    Front Aging Neurosci; 2017; 9():210. PubMed ID: 28701950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
    ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left Ventricular Ejection Fraction and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Normal Older Adults: The CABLE Study.
    Zheng YM; Zhao YY; Zhang T; Hou XH; Bi YL; Ma YH; Xu W; Shen XN; Dong Q; Tan L; Yu JT
    J Alzheimers Dis; 2021; 81(2):743-750. PubMed ID: 33814430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anaemia and cerebrospinal fluid biomarkers of Alzheimer's pathology in cognitively normal elders: the CABLE study.
    Yang XY; Hou XH; Bi YL; Hu H; Cao XP; Tan L; Yang JL; Yu JT
    BMC Neurol; 2021 Nov; 21(1):454. PubMed ID: 34794413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology.
    Sato C; Mallipeddi N; Ghoshal N; Wright BA; Day GS; Davis AA; Kim AH; Zipfel GJ; Bateman RJ; Gabelle A; Barthélemy NR
    Ann Clin Transl Neurol; 2021 Sep; 8(9):1817-1830. PubMed ID: 34342183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
    J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.